BIOPHARMA
ByAI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
How Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5 Years?
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
What If HER2 Resistance Was Over? Henlius Doses First Patient in Phase 2/3 HLX22 Trial, Unleashing Multi-Oncology Disruption
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
Is Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
